Gossamer Bio stock upgraded at UBS (GOSS:NASDAQ)

Group 1 - Gossamer Bio's shares increased after UBS upgraded the stock from Neutral to Buy, indicating a positive outlook for the company [2] - The upgrade is based on an "underappreciated" late-stage data catalyst related to Gossamer Bio's lead asset, seralutinib [2] - This upgrade comes at a strategic time for the company, suggesting potential for growth and investor interest [2]